AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03041402 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PSN
Description: PSN, setting the NAVA level at its maximum (i.e; 15 cmH2O/mcV), and an upper Paw limit such to obtain the same overall Paw applied during PSP
Study NCT04676841 — intervention group
Intervention type: DEVICE
Intervention: Conventional ventilation + instrumental tables with integrated laminar airflow
Description: Surgical instruments protected from contamination by local laminar airflow
Study NCT04676841 — intervention group
Intervention type: DEVICE
Intervention: Conventional ventilation + standard instrumental tables
Description: Control
Study NCT04676841 — intervention group
Intervention type: DEVICE
Intervention: Laminar airflow ventilation + standard instrumental tables
Description: Control
Study NCT01502878 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nut challenge
Description: Nut powder made from non-roasted nuts and roasted banana mixed with oats yoghurt or chocolate pudding
Study NCT01502878 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nut challenge: Placebo
Description: Dried banana mixed with oat yoghurt or chocolate pudding
Study NCT01502878 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nut oral desensitization
Description: Roasted peanut powder mixed with milk- and soy-free margarine
Study NCT02725814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 24% Sucrose Solution
Description: Two minutes prior to the start of a painful procedure neonates will receive 0.12ml of 24% sucrose solution, over a period of no more than 1 minute. A pacifier will be offered immediately following sucrose administration for non-nutritive sucking if the infant is able to hold the pacifier securely. The sucrose study dose is to be repeated as needed based on pain response and procedure duration.
Study NCT03628144 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Impact® Advanced Recovery
Description: The intervention drink Impact® will be ingested every two weeks since usually chemotherapy is delivered concurrently with radiation therapy in 2 week cycles. For patients who are placed on weekly or every 4 weeks chemotherapy dosing schedules, the treatment and control supplements will still be given every two weeks.
Study NCT03628144 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Boost® High Protein
Description: The control supplement drink Boost® will be ingested every two weeks since usually chemotherapy is delivered concurrently with radiation therapy in 2 week cycles. For patients who are placed on weekly or every 4 weeks chemotherapy dosing schedules, the treatment and control supplements will still be given every two weeks.
Study NCT03628144 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Standard of Care: Weekly radiation therapy as already planned for each participant, at Moffitt clinic visits.
Study NCT03628144 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Standard of Care: Weekly radiation therapy as already planned for each participant, at Moffitt clinic visits.
Study NCT03628144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Standard of Care: Chemotherapy as already planned for each participant.
Study NCT03628144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Standard of Care: Chemotherapy as already planned for each participant.
Study NCT03628144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life (EORTC-QLQ-30)
Description: Participants will undergo pre- and post-treatment assessments.
Study NCT03628144 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality of life (EORTC-QLQ-30)
Description: Participants will undergo pre- and post-treatment assessments.
Study NCT03628144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of Cognitive Function (FACT-Cog, v. 3.0)
Description: Participants will undergo pre- and post-treatment assessments.
Study NCT03628144 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of Cognitive Function (FACT-Cog, v. 3.0)
Description: Participants will undergo pre- and post-treatment assessments.
Study NCT03628144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Questionnaire (FFMQ)
Description: Participants will undergo pre- and post-treatment assessments.
Study NCT03628144 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Questionnaire (FFMQ)
Description: Participants will undergo pre- and post-treatment assessments.
Study NCT01310543 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teens and Toddlers
Description: The T\&T intervention aims to prevent teenage pregnancy and promote sexual health by providing young women at risk of teenage pregnancy with regular and direct contact with a toddler and combines this with 12 modules of group-based personal-development sessions involving communication skills, anger management, discussion of positive sexual health and relationships, culminating in an accredited National Award in Interpersonal Skills. One-to-one life coaching is also provided. The intervention consists of 20 weekly afternoon sessions run in nurseries near to the secondary schools from which participating young women are recruited.
Study NCT02052336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CJ-12420 200mg + Clarithromycin 500mg
Description: To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
Study NCT02052336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 200mg
Description: To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
Study NCT02052336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CJ-12420 200mg
Description: To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
Study NCT02052336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500mg
Description: To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
Study NCT02052336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin 500mg
Description: To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
Study NCT02260778 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learning Collaborative
Description: A learning collaborative is an established technique that uses the model for improvement to bridge the gap between what we know and what we do. Structured learning sessions and collaborative coaching are used to guide small cycles of change called Plan-Do-Study-Act (PDSA) cycles. This quality improvement intervention will help providers adopt treat-to-target practices through the structured learning collaborative.
Study NCT02154100 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tart Cherry
Description: 12 weeks of tart cherry juice taken in two doses of 240 ml per day.
Study NCT02154100 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12 weeks of tart cherry juice taken in two doses of 240 ml per day.
Study NCT02480491 — intervention group
Intervention type: OTHER
Intervention: measuring cell freeDNA
Description: measuring cell free DNA using PCR
Study NCT01969383 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heated pool training
Study NCT03420391 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation Therapy (PBMT)
Description: Phototherapy device - Multi Radiance Medical® (Solon, OH, EUA)
Study NCT03420391 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Photobiomodulation Therapy (PBMT)
Description: Phototherapy device - Multi Radiance Medical® (Solon, OH, EUA)
Study NCT03651856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATM FOG in PD
Description: open label pilot study on atomoxetine 40mg BID on patients with Parkinson's disease and Freezing of Gait
Study NCT00856089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retapamulin
Description: Retapamulin ointment, 1%, apply a thin layer, BID for 5 days
Study NCT05519436 — intervention group
Intervention type: OTHER
Intervention: Assessment
Description: Bioelectrical impedance analysis method was used to evaluate the body composition of the cases. Muscle, fat, water ratio was made with Inbody Bioelectrical Impedance Device. Static and dynamic plantar pressure analyzes were evaluated with Sensor Medica pedobarographic measuring device, and postural sway was evaluated with bilateral comparison tests, one of the dynamic balance tests of Biodex Balance System.
Study NCT02655523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: 1 mL of 40 mg of Triamcinolone
Study NCT02655523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 1 mL of 4mg of Dexamethasone
Study NCT02655523 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 1 mL of preservative free normal saline
Study NCT02655523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 2 mL of 0.5% bupivacaine
Study NCT02655523 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: 2 mL of 0.5% bupivacaine
Study NCT02839577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Volume injection without corticosteroid
Description: Injection with 10 mls 0.5% bupivacaine hydrochloride and~• 40 ml saline around the tendon.
Study NCT02839577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Volume injection with corticosteroid
Description: Injection with 10 mls 0.5% bupivacaine hydrochloride, 20 mg Depomedrol and 40 ml saline around the tendon.
Study NCT03041402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PSN
Description: PSN, setting the NAVA level at its maximum (i.e; 15 cmH2O/mcV), and an upper Paw limit such to obtain the same overall Paw applied during PSP
Study NCT02408640 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cannabishjalpen.se
Study NCT00451048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given orally
Study NCT00856375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-102
Description: IV every 3 weeks
Study NCT01349322 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard fractionation whole breast irradiation
Description: Target-based radiation using three-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) to deliver 25 fractions of 2.0 Gy for a total dose of 50.0 Gy or 16 fractions of 2.67 Gy for a total dose of 42.7 Gy. Must begin within 9 weeks of last surgery or chemotherapy delivery.
Study NCT00856375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan
Description: IV every 3 weeks
Study NCT02174289 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Targeted left ventricular endocardial lead placement
Description: The left ventricular endocardial lead will be passed through the intra-atrial septum
Study NCT02174289 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Targeted left ventricular endocardial lead placement
Description: The left ventricular endocardial lead will be passed through the intra-atrial septum
Study NCT02493192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pethidine and haloperidol injection
Study NCT02493192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: birth ball
Study NCT01882972 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT01882972 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Meditation
Study NCT04715269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam
Description: Alprazolam 0.5 mg will be given when the patient with acute coronary syndrome would present to the emergency
Study NCT04715269 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Empty capsule
Study NCT02201888 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive training
Description: Treatment lasted six months. The CRT and CC conditions consisted of biweekly sessions of 45 minutes. Patients in both conditions trained in groups of up to 8, supervised by a single person. The CRT and CC groups were scheduled at different times. The same personnel supervised both treatment conditions. All supervisors were trained by the coordinator of the study in the technical management of the two conditions.
Study NCT01400802 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Dosage form- Subcutaneous Injection
Study NCT01400802 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Dosage form- Subcutaneous Injection
Study NCT01890447 — intervention group
Intervention type: OTHER
Intervention: Web-based survey questionnaire
Description: Data collection will be done via web-based questionnaires generated by Sawtooth Software. Subjects will be asked for their ideal alternative (acceptance to immunisation) by selecting the factors that suit them the most. The subjects are then presented several sets of alternatives built around their ideal choice.
Study NCT02317289 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Detection of freezing
Description: single wireless inertial sensor placed on the patients's lower limbs to detect freezing of gaitin Parkinsonian patients
Study NCT04920500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Cytarabine liposome for injection
Description: Induction 1: \[100 U/m²\] i.v. d1,3,5 Induction 2: \[100 U/m²\] i.v. d1,3
Study NCT04920500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vyxeos、Daunorubicin Cytarabine liposome for injection
Description: Induction 1: \[100 U/m²\] i.v. Vyxeos（d1）,Daunorubicin Cytarabine liposome for injection（d3、d5） Induction 2: \[100 U/m²\] i.v. Daunorubicin Cytarabine liposome for injection（d1、d3 ）
Study NCT01422187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa
Description: Taliglucerase infusion every two weeks for 21 months
Study NCT03578549 — intervention group
Intervention type: DEVICE
Intervention: Pulse Oximetry
Description: Pulse Oximeter is being applied with a special holding tool to test the oximeter for its ability to measure pulpal blood flow, but no effect of the oximeter is being measured. Thus, to that degree the use is observational rather than interventional.
Study NCT01820975 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High protein intake
Study NCT01820975 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: No protein intake
Study NCT03585634 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Dads in Gear Program
Study NCT02201888 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Computerized active condition
Description: Treatment lasted six months. The CRT and CC conditions consisted of biweekly sessions of 45 minutes. Patients in both conditions trained in groups of up to 8, supervised by a single person. The CRT and CC groups were scheduled at different times. The same personnel supervised both treatment conditions. All supervisors were trained by the coordinator of the study in the technical management of the two conditions.
Study NCT02201888 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: TAU: Patients in this condition participated in their (individually variable) daily rehabilitative activities. Patients allocated to the other two conditions also participated in these activities.
Study NCT03464955 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology Based Distractions
Description: Technology based distractions (VR headsets, AR headset, tablets, or BERT projector)
Study NCT01349322 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated whole breast irradiation
Description: Target-based radiation using three-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) to deliver 15 fractions of 2.67 Gy for a total dose of 40.0 Gy. Must begin within 9 weeks of last surgery or chemotherapy delivery.
Study NCT01349322 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent boost
Description: 15 fractions of 3.2 Gy for a total dose of 48 Gy to the lumpectomy cavity. Given concurrently with treatment to the entire breast. May be given by either electron beam or photon beams using either 3D-CRT or IMRT.
Study NCT01349322 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Sequential boost
Description: 6 fractions of 2.0 Gy per fraction for a total dose of 12 Gy or 7 fractions of 2.0 Gy for a total dose of 14 Gy to the lumpectomy cavity. May be given by either electron beam or photon beams using either 3D-CRT or IMRT. Begins without a treatment break after completion of the treatment to the entire breast.
Study NCT03127774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Route of administration: Intraperitoneal for tumor treatment. Dose of 250 mg/m2~Drug 1 of the hyperthermic intraperitoneal chemotherapy (HIPEC)
Study NCT03127774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate
Description: Route of administration: Intravenous Loading dose of 7.5 gm/m2 over 20 minutes followed by 2.13 gm/m2/hr for 12 hours~Drug 2 given intravenously during hyperthermic intraperitoneal chemotherapy (HIPEC)
Study NCT03127774 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery
Description: Standard of care: Surgical procedure used to remove tumors from patients with peritoneal tumors.
Study NCT04751409 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest Radiography
Description: Undergo CXR
Study NCT04751409 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT-chest
Study NCT01373372 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Acthrel
Description: Powder for reconstitution, 1.0 mcg/kg body weight to a maximum of 100 mcg, delivered one time via IV over one minute.
Study NCT01373372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthrel
Description: Powder for reconstitution, 1.0 mcg/kg body weight to a maximum of 100 mcg, delivered one time via IV over one minute.
Study NCT04751409 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Follow-Up
Description: Undergo intense follow-up
Study NCT00345254 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: severing cord
Description: The cord was cut intentionally after delivery of the anterior shoulder and prior to extraction of the body.
Study NCT02981498 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion chemotherapy
Description: administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
Study NCT02981498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfox Protocol
Description: Oxaliplatin , fluorouracil, and leucovorin
Study NCT02305511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral venous catheterization
Description: Cannulation using standard method
Study NCT02305511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jamshidi
Description: intraosseous access using the Jamshidi device
Study NCT02305511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIG
Description: intraosseous access using the BIG device
Study NCT02305511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cook
Description: intraosseous access using the Cook device
Study NCT02305511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EZIO
Description: intraosseous access using the EZIO device
Study NCT03284359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-Consent Nudge Bundle
Description: The pre-consent nudge bundle survey was developed by the study team and incorporates several behavioral interventions into a bundle of 5 types of nudges: (i) injunctive norms; (ii) descriptive norms; (iii) duty of reciprocity; (iv) self-prophecy; and (v) foot-in-the-door. Injunctive norms involve the perception of what behavior is acceptable, while descriptive norms highlight what behaviors others are engaging in. The duty of reciprocity is the sense that one should repeat pro-social behavior for which they have benefited from. The foot-in-the-door nudge involves asking a participant to perform a small request which has a high consent rate followed by a larger request. The bundle consists of six questions and one statement.
Study NCT04011930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: 80,000 IU(2 capsules)/week for 13 weeks and then according to the serum calcium and serum D level 40,000 IU/2 to 3 weeks for next 13 weeks
Study NCT04011930 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: 80,000 IU(2 capsules)/week for 13 weeks and then according to the serum calcium and serum D level 40,000 IU/2 to 3 weeks for next 13 weeks